ATE257013T1 - Verwendung von botulinum-toxin zur behandlung von diabetes - Google Patents

Verwendung von botulinum-toxin zur behandlung von diabetes

Info

Publication number
ATE257013T1
ATE257013T1 AT01903262T AT01903262T ATE257013T1 AT E257013 T1 ATE257013 T1 AT E257013T1 AT 01903262 T AT01903262 T AT 01903262T AT 01903262 T AT01903262 T AT 01903262T AT E257013 T1 ATE257013 T1 AT E257013T1
Authority
AT
Austria
Prior art keywords
botulinum toxin
treat diabetes
diabetes
treat
botulinum
Prior art date
Application number
AT01903262T
Other languages
German (de)
English (en)
Inventor
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE257013T1 publication Critical patent/ATE257013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01903262T 2000-01-26 2001-01-24 Verwendung von botulinum-toxin zur behandlung von diabetes ATE257013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/491,420 US6337075B1 (en) 2000-01-11 2000-01-26 Methods for treating diabetes
PCT/US2001/002273 WO2001054711A2 (en) 2000-01-26 2001-01-24 Use of neurotoxins for treating diabetes

Publications (1)

Publication Number Publication Date
ATE257013T1 true ATE257013T1 (de) 2004-01-15

Family

ID=23952146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01903262T ATE257013T1 (de) 2000-01-26 2001-01-24 Verwendung von botulinum-toxin zur behandlung von diabetes

Country Status (11)

Country Link
US (2) US6337075B1 (enExample)
EP (1) EP1250146B1 (enExample)
JP (1) JP4851042B2 (enExample)
AR (1) AR029464A1 (enExample)
AT (1) ATE257013T1 (enExample)
AU (1) AU2001231104A1 (enExample)
DE (1) DE60101669T2 (enExample)
DK (1) DK1250146T3 (enExample)
ES (1) ES2211765T3 (enExample)
TW (1) TWI233806B (enExample)
WO (1) WO2001054711A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
KR100753765B1 (ko) * 2000-02-08 2007-08-31 알레간 인코포레이티드 보툴리눔 독소 약제학적 조성물
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6492339B1 (en) * 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
US6486127B1 (en) * 2001-05-23 2002-11-26 Insmed, Incorporated Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
PL370686A1 (en) 2001-11-15 2005-05-30 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CA2607589A1 (en) * 2004-05-07 2005-11-24 Phytotox Limited Methods of treating wounds with gonyautoxins
WO2005110418A2 (en) * 2004-05-07 2005-11-24 Phytotox Limited Transdermal administration of phycotoxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
WO2006130161A2 (en) * 2004-07-21 2006-12-07 The Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
WO2006026780A1 (en) 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
US8052979B2 (en) 2005-03-15 2011-11-08 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
WO2009002437A2 (en) * 2007-06-25 2008-12-31 The Board Of Regents Of The University Of Texas System Neurotoxin theraphy for postprandial hyperglycemia
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2972928B1 (fr) * 2011-03-25 2013-11-29 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
RU2733493C2 (ru) 2015-01-09 2020-10-02 Ипсен Байоинновейшн Лимитед Катионные нейротоксины
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
US20210277071A1 (en) 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
CN111465352B (zh) 2018-02-26 2024-04-12 益普生生物制药有限公司 使用超声波引导非细胞毒性蛋白酶的注射
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
EP4045073A4 (en) 2019-10-18 2022-12-07 Penland Foundation Botulinum toxin for use in treatment
US20220143158A1 (en) * 2020-09-18 2022-05-12 Vanderbilt University Duodenal administration of botulinum toxin
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2023287728A1 (en) * 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
WO2023287729A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of acute and chronic kidney disease
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
DE69434443T2 (de) 1993-12-28 2006-05-24 Allergan, Inc., Irvine Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
AU6034396A (en) 1995-06-06 1996-12-24 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin

Also Published As

Publication number Publication date
AR029464A1 (es) 2003-07-02
EP1250146A2 (en) 2002-10-23
US6416765B1 (en) 2002-07-09
DK1250146T3 (da) 2004-04-26
ES2211765T3 (es) 2004-07-16
EP1250146B1 (en) 2004-01-02
WO2001054711A3 (en) 2002-02-21
AU2001231104A1 (en) 2001-08-07
JP4851042B2 (ja) 2012-01-11
US6337075B1 (en) 2002-01-08
WO2001054711A2 (en) 2001-08-02
JP2003520822A (ja) 2003-07-08
TWI233806B (en) 2005-06-11
US20020031529A1 (en) 2002-03-14
DE60101669D1 (de) 2004-02-05
DE60101669T2 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
ATE257013T1 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
ATE473753T1 (de) Verwendung von botulinum toxin zur behandlung von post-operative schmerzen
ATE245032T1 (de) Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE60140516D1 (de) Behandlung von fluorkohlenstoff- ausgangsmaterialien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE526982T1 (de) Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE339955T1 (de) Verwendung von escitalopram zur behandlung von generalisierten angstzuständen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60104791D1 (de) Cyclobutendion-Derivate zur Behandlung von Artherosclerose
EP1315503A4 (en) TREATMENT AGAINST URINARY DYSFUNCTION
DE60103685D1 (de) Behandlung von Poriomania
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
ATE317261T1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE267608T1 (de) Verwendung von fsh zur behandlung von infertilität
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
DE60012836D1 (de) Verwendung von Simethicone zur Behandlung der ulzerativen Kolitis
EP1359910A4 (en) PROCESS FOR THE TREATMENT OF GLAUCOM II B
ATE290874T1 (de) Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
DE50003481D1 (de) Verwendung von schmutzablösenden formulierungen zur behandlung von oberflächen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties